Segment Data (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The Company has identified the following significant segment expenses (SSEs) due to their relevance to the overall consolidated operating results (in thousands):

	Years Ended December 31,
	2025		2024		2023
Net sales from external customers	$	602,797	$	504,421	$	400,072
Significant segment expenses:
Materials	244,316		219,755		181,434
Salaries and Benefits	183,349		133,984		103,387
Depreciation and amortization	19,150		14,715		11,407
Interest expense, net	9,804		8,061		3,645
Other segment items (a)	63,665		54,881		46,297
Income before income tax provision	82,513		73,025		53,902
Income tax provision	14,200		14,044		8,978
Segment net income	$	68,313	$	58,981	$	44,924
Segment total assets (b)	$	655,077	$	628,995	$	404,136

(a)Other segment items include (production overhead, stock compensation, professional fees, and other SG&A expenses)

(b)See Consolidated Balance Sheet for details

Schedule of Revenue by Major Customers by Reporting Segments

The Company’s products are primarily sold to customers within the Medical and Non-medical markets. Net sales by market for the years ended December 31, 2025, 2024 and 2023 are as follows (in thousands):

	2025				2024				2023
Market	Net Sales		%		Net Sales		%		Net Sales		%
Medical	$	555,323	92.1	%	$	450,767	89.4	%	$	346,355	86.6	%
Non-medical	47,474		7.9	%	53,654		10.6	%	53,717		13.4	%
Net Sales	$	602,797	100.0	%	$	504,421	100.0	%	$	400,072	100.0	%